高级搜索

74例淋巴母细胞淋巴瘤的临床特点及预后分析

袁英, 臧立, 岳智杰, 张翼鷟, 王晓芳

袁英, 臧立, 岳智杰, 张翼鷟, 王晓芳. 74例淋巴母细胞淋巴瘤的临床特点及预后分析[J]. 肿瘤防治研究, 2018, 45(3): 154-159. DOI: 10.3971/j.issn.1000-8578.2018.17.0751
引用本文: 袁英, 臧立, 岳智杰, 张翼鷟, 王晓芳. 74例淋巴母细胞淋巴瘤的临床特点及预后分析[J]. 肿瘤防治研究, 2018, 45(3): 154-159. DOI: 10.3971/j.issn.1000-8578.2018.17.0751
YUAN Ying, ZANG Li, YUE Zhijie, ZHANG Yizhuo, WANG Xiaofang. Clinical Features and Prognosis of 74 Cases of Lymphoblastic Lymphoma[J]. Cancer Research on Prevention and Treatment, 2018, 45(3): 154-159. DOI: 10.3971/j.issn.1000-8578.2018.17.0751
Citation: YUAN Ying, ZANG Li, YUE Zhijie, ZHANG Yizhuo, WANG Xiaofang. Clinical Features and Prognosis of 74 Cases of Lymphoblastic Lymphoma[J]. Cancer Research on Prevention and Treatment, 2018, 45(3): 154-159. DOI: 10.3971/j.issn.1000-8578.2018.17.0751

74例淋巴母细胞淋巴瘤的临床特点及预后分析

基金项目: 

国家自然科学基金 81272562

详细信息
    作者简介:

    袁英(1992-),女,硕士在读,主要从事血液系统恶性肿瘤的研究

    通讯作者:

    王晓芳,E-mail: XiaofangWangyy@163.com

  • 中图分类号: R733.1

Clinical Features and Prognosis of 74 Cases of Lymphoblastic Lymphoma

More Information
  • 摘要:
    目的 

    分析淋巴母细胞淋巴瘤(lymphoblastic lymphoma, LBL)的临床特点,比较B淋巴母细胞淋巴瘤(B lymphoblasts lymphoma, B-LBL)与T淋巴母细胞淋巴瘤(T lymphoblasts lymphoma, T-LBL)的临床及预后特点及不同化疗方案对LBL的预后影响。

    方法 

    选择2007—2014年天津医科大学肿瘤医院收治的74例经免疫组织化学确诊为LBL的患者。采用描述统计方法分析LBL的疾病谱特征。

    结果 

    74例LBL患者的中位年龄为19.5岁,其中45例为男性,60例为晚期起病(Ann-Arbor分期Ⅲ~Ⅳ期),42例存在B症状,32例发生骨髓受累。治疗总有效率为70.2%,完全缓解率为48.6%,3年和5年总生存率(overall survival, OS)分别为38.0%和26.6%,3年和5年无进展生存率(progression-free survival, PFS)分别为34.8%和23.2%。其中B-LBL患者17例,T-LBL患者57例。B-LBL较T-LBL更倾向发生于儿童,起病时多伴有贫血,二者生存意义比较差异无统计学意义。单因素分析显示年龄是否小于18岁、有无贫血、β2微球蛋白水平、诱导治疗方案、近期疗效为预后相关因素。

    结论 

    淋巴母细胞淋巴瘤是一种高度侵袭性的恶性非霍奇金淋巴瘤,生存期短,多发生于青少年,起病时多为晚期,易发生骨髓转移。采用ALL类化疗方案的患者预后可能优于CHOP样方案。

     

    Abstract:
    Objective 

    To analyze clinical features of lymphoblastic lymphoma(LBL), compare clinical and prognostic characteristics of B lymphoblasts lymphoma (B-LBL) and T lymphoblasts lymphoma (T-LBL), and the prognosis of various chemotherapy regimens on LBL.

    Methods 

    Total 74 patients with LBL were collected from 2007 to 2014 at Tianjin Medical University Cancer Institute and Hospital. Descriptive analysis was used to analyze the disease spectrum characteristics of LBL.

    Results 

    The median age of 74 LBL patients was 19.5 years, among which 45 cases were male, 60 cases were late onset (Ann-Arbor stage Ⅲ-Ⅳ), 42 patients had B symptoms, 32 cases had bone marrow involvement. The overall response rate (ORR) of the whole group was 70.2%, the complete response rate was 48.6%, and the 3-and 5-year overall survival rates were 38.0% and 26.6%, respectively. The 3-and 5-year progression-free survival rates were 34.8% and 23.2%, respectively. Seventeen patients were B-LBL and 57 cases were T-LBL. Compared with T-LBL, B-LBL was more likely to occur in children and associated with the onset of anemia. There was no significant difference in the survival between B-LBL and T-LBL patients. Univariate analysis showed that whether age < 18 years old, whether with anemia, the level of β2-MG, induction therapy regimens, the short-term efficacy were the related factors for prognosis.

    Conclusion 

    Lymphoblastic lymphoma is a highly aggressive malignant non-Hodgkin' s lymphoma, with short lifetime, easy to occur in young people, usually late in the onset of the disease prone to bone marrow metastasis. Patients with ALL chemotherapy regimens may have better prognosis than those with CHOP-like regimens.

     

  • 宫颈小细胞神经内分泌癌(small cell neuroendocrine carcinoma, SCNEC)是一种较为罕见的原发于宫颈的神经内分泌性肿瘤,约占宫颈恶性肿瘤的1%~2%[1-2]。在各种类型的宫颈癌中,SCNEC是一种侵袭性强的病理类型[3-8]。但因为该类病例较少,目前尚无规范化的治疗。本研究对101例宫颈小细胞神经内分泌癌患者的临床病理资料及生存状况进行分析,旨在探讨SCNEC合理的治疗方案及预后相关因素,为此类患者治疗及预后判断提供临床依据。

    收集2007年1月—2018年6月在江西省妇幼保健院确诊并完成治疗的101例宫颈小细胞神经内分泌癌患者作为研究对象。患者确诊年龄25~73岁,中位年龄44岁,其中41~50岁者有40例。宫颈局部肿瘤直径 > 4 cm患者34例,≤4 cm患者67例。患者临床资料及年龄分布见表 1。所有患者均知情同意。

    表  1  101例SCNEC患者临床病理特征
    Table  1  Clinical and pathological features of 101 SCNEC patients
    下载: 导出CSV 
    | 显示表格

    (1)所有患者接受治疗前均经江西省妇幼保健院病理确诊为宫颈小细胞神经内分泌癌;(2)临床分期盆腔检查均经三位以上有经验的妇科肿瘤专业医师检查确定;(3)治疗前均未接受任何干预性治疗,且初始治疗及后续治疗均在同一机构完成;(4)纳入研究的患者治疗模式均为手术+术后补充放化疗(下文简称手术治疗组)或根治性放化疗,且按计划完成全部治疗;(5)全部患者术后病理检查均在同一医院完成;(6)建立了完整的病历档案,并持续随访,具备完整的住院及门诊复查病历资料。

    72例手术治疗患者手术方式为广泛子宫切除+盆腔淋巴结切除术±腹主动脉旁淋巴结切除术,其中47例行腹主动脉旁淋巴结切除术。69例行双附件切除,其余3例保留一侧卵巢且进行了保留卵巢的组织活检。

    放疗包括体外照射+腔内后装治疗,体外照射采用全盆腔体外照射+中央遮盖体外照射。体外照射剂量:全盆照射肿瘤剂量30~40 Gy,中央遮盖照射剂量15~25 Gy,放疗频率及强度:每周5次,每次分割剂量2 Gy。腔内后装采用高剂量率后装治疗设备,放射源为铱192。放疗剂量参照点A点累积剂量要求60~70 Gy;B点累积剂量要求54~56 Gy。放疗期间均给予铂类为基础的同步化疗。

    通过电话或门诊复查方式进行随访,截止时间为2018年9月。

    采用GraphPad7.0统计软件对不同组间患者生存率进行显著性比较。生存分析采用Kaplan-Meier法,生存率的比较采用Log rank检验。P < 0.05为差异有统计学意义。

    72例手术组患者中,2例失访,19例死亡,51例生存。19例死亡患者生存时间1~63月,中位生存时间19月,平均生存时间18.5月。51例生存的患者中,生存时间1~139月,中位生存时间39月,平均生存时间47.3月。随访5年以上共33例,生存20例,五年生存率60.6%。

    29例根治性放化疗患者中,随访5年以上20例,其中2例失访,死亡15例,生存3例,五年生存率15%。生存时间1~75月,中位生存时间21月。3例生存患者年龄分别为40岁、41岁、46岁,临床分期均为ⅡB期,病理均为单纯的宫颈小细胞神经内分泌癌,化疗方案均为多西他赛+卡铂,放疗给予根治性同步放化疗。ⅠB1期~ⅡA期手术治疗组患者生存率优于ⅡB期~Ⅳ期期根治性放化疗组患者(P=0.0025),见图 1

    图  1  手术组与放化疗组患者生存曲线图
    Figure  1  Survival curves of Surgery and CCRT groups

    72例接受手术治疗的患者均行宫颈癌根治术+盆腔淋巴结切除术,47例行腹主动脉旁淋巴结切除术,其中1例(1/47, 2.12%)腹主动脉旁淋巴结阳性。27例(27/72, 37.5%)盆腔淋巴结阳性。淋巴结阳性与阴性患者生存曲线比较差异有统计学意义,淋巴结阴性患者生存优于淋巴结阳性患者(P=0.0004),见图 2

    图  2  盆腔淋巴结阳性和阴性手术患者生存曲线
    Figure  2  Survival curves of surgical SCNEC patients with pelvic lymph node positive and negative

    72例手术治疗的患者中,按病理类型分,单纯SCNEC例41例,混合其他病理类型者31例,其中混合有腺癌19例,鳞癌9例,腺鳞癌3例。混合型与单纯型SCNEC生存曲线比较差异无统计学意义(P=0.0546),见图 3

    图  3  单纯型与混合型SCNEC生存曲线
    Figure  3  Survival curves of pure and mixed type SCNEC patients

    WHO分类将宫颈神经内分泌肿瘤分为低级别神经内分泌肿瘤(包括类癌及非典型类癌)和高级别神经内分泌肿瘤(包括小细胞神经内分泌癌和大细胞神经内分泌癌)。目前无公认的、规范有效的治疗方案,对于宫颈神经内分泌肿瘤多参照常见宫颈癌的分期治疗原则,主张手术、化疗和放疗的综合性治疗,但其治疗是否应有别于宫颈鳞癌需要更大样本、多中心的研究。美国国立综合癌症网络(National Comprehensive Cancer Network, NCCN)指南也将SCNEC列入特殊类型宫颈癌。

    关于SCNEC患者生存率及预后方面的研究,Ishikawa等的一项多中心研究显示淋巴血管间隙受侵是患者的总生存率及无进展生存率的重要预后因素,盆腔淋巴结转移是DFS的重要预后影响因素[9]。Cohen等研究发现Ⅰ~ⅡA、ⅡB~ⅣA、ⅣB期5年生存率分别为36.8%、9.8%和0[10],本研究结果显示临床分期与预后密切相关,各期别5年生存率均较以往文献报道略高。FIGO分期是较为公认的影响患者预后的最重要的独立危险因素[11-12]。由于SCNEC侵袭性强,易发生远处转移,有学者认为早期SCNEC患者手术联合化疗的预后优于单纯手术者[13-14]。本研究中ⅠB~ⅡA期患者均采用手术+放化疗综合治疗,5年总生存率60%以上,提示手术联合术后放化疗对此类患者疗效较好。

    宫颈小细胞神经内分泌癌早期容易发生转移,但从72例早期患者手术情况发现,仅1例(1.39%)发生卵巢转移。提示对于存在生育要求的年轻SCNEC患者,是否一定要行卵巢切除有待进一步研究证实。研究证实,SCNEC好发转移器官为肺、脑、肝,预后差[15-16]

    此外,几乎所有文献均支持此类肿瘤早期即容易发生远处转移,本研究资料中,死亡病例主要病因为肺转移、全身转移,临床观察也支持上述观点。关于淋巴结转移,有研究认为,即使是早期的SCNEC患者,淋巴结转移也非常普遍,淋巴结转移率为41.6%~57%[17]。本研究中,72例早期SCNEC患者手术后病理提示淋巴结转移22例,转移率37.5%,与文献报道接近,但是对于腹主动脉旁淋巴结,72例患者中47例患者行腹主动脉旁淋巴结活检或切除,仅1例发生腹主动脉旁淋巴结转移,转移率仅为2.13%,远低于盆腔淋巴结转移率。这一研究结果提示我们,即便是早期SCNEC患者,化疗对于控制转移也有重要的临床意义。

    与以往报道相比,本研究中手术患者术后均补充了放化疗,且均达到6个疗程,其中49例采用紫杉醇+铂类化疗方案,23例采用顺铂+环磷酰胺+表阿霉素化疗方案,提示手术后放化疗的必要性。

    总之,宫颈小细胞神经内分泌癌发病率低、恶性程度高、易发生远处转移和复发,患者预后差、死亡率高、有独特的病理特征,诊断主要依据病理诊断和免疫组织化学结果可提高其诊断的准确率。由于研究样本少,尚需大量的临床资料及多中心研究探索最佳早期诊断及治疗的方法。

  • 图  1   淋巴母细胞淋巴瘤患者的3年和5年OS与PFS

    Figure  1   3-and 5-year OS and PFS of patients with lymphoblastic lymphoma

    图  2   ALL类方案与CHOP样方案的OS与PFS

    Figure  2   OS and PFS of ALL classes and CHOP-like regimen

    图  3   淋巴母细胞淋巴瘤患者不同疗效的OS与PFS

    Figure  3   OS and PFS of LBL patients with different therapeutic efficacy

    表  1   淋巴母细胞淋巴瘤的临床特征

    Table  1   Clinical characteristic of lymphoblastic lymphoma patients

    下载: 导出CSV

    表  2   B-LBL与T-LBL临床特点比较

    Table  2   Comparison of clinical characteristic between B-LBL and T-LBL patients

    下载: 导出CSV

    表  3   单因素和多因素生存分析

    Table  3   Univariate and multivariate survival analyses

    下载: 导出CSV
  • [1]

    Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview[J]. Pathologica, 2010, 102(3): 83-7. https://www.ncbi.nlm.nih.gov/pubmed/?term=WHO+classification+of+tumours+of+haematopoietic+and+lymphoid+tissues+in+2008%3A+an+overview.

    [2] 苏丽萍.淋巴母细胞淋巴瘤生物学特征与治疗进展[J].中国实用内科杂志, 2015, 35(2): 102-6. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=synk201502007&dbname=CJFD&dbcode=CJFQ

    Su LP. Biological characteristics and treatment progress of lymphoblastic lymphoma[J]. Zhongguo Shi Yong Nei Ke Za Zhi, 2015, 35(2): 102-6. http://kns.cnki.net/KCMS/detail/detail.aspx?filename=synk201502007&dbname=CJFD&dbcode=CJFQ

    [3]

    Maitra A, McKenna RW, Weinberg AG, et al. Precursor B-cell lymphoblastic lymphoma. A study of nine cases lacking blood and bone marrow involvement and review of the literature[J]. Am J Clin Pathol, 2001, 115(6): 868-75. doi: 10.1309/Q5GV-3K00-WAC6-BBUB

    [4]

    Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma[J]. J Clin Oncol, 2007, 25(5): 579-86. doi: 10.1200/JCO.2006.09.2403

    [5]

    Belgaumi AF, Al-Kofide A, Sabbah R, et al. Precursor B-cell lymphoblastic lymphoma (PBLL) in children: pattern of presentation and outcome[J]. J Egypt Natl Canc Inst, 2005, 17(1): 15-9. https://www.researchgate.net/publication/7417103_Precursor_B-cell_lymphoblastic_lymphoma_PBLL_in_children_Pattern_of_presentation_and_outcome

    [6]

    Recine M, Castellano-Sanchez AA, Sheldon J, et al. Precursor B-cell lymphoblastic lymphoma/leukemia presenting as osteoblastic bone lesions[J]. Ann Diagn Pathol, 2002, 6(4): 236-43. doi: 10.1053/adpa.2002.34733

    [7]

    Lee WJ, Moon HR, Won CH, et al. Precursor B-or T-lymphoblastic lymphoma presenting with cutaneous involvement: a series of 13 cases including 7 cases of cutaneous T-lymphoblastic lymphoma[J]. J Am Acad Dermatol, 2014, 70(2): 318-25. doi: 10.1016/j.jaad.2013.10.020

    [8]

    Burkhardt B, Reiter A, Landmann E, et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group[J]. J Clin Oncol, 2009, 27(20): 3363-9. doi: 10.1200/JCO.2008.19.3367

    [9] 胡原, 赵夏, 吴丽莉, 等. Hyper CVAD方案和CHOP方案治疗淋巴母细胞淋巴瘤的效果分析[J].四川大学学报(医学版), 2014, 45(4): 680-4. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201014011

    Hu Y, Zhao X, Wu LL, et al. Comparison of HyperCVAD regimen and CHOP regimen in treating patients with lymphoblastic lymphoma[J]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2014, 45(4): 680-4. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201014011

    [10] 孙晓非, 甄子俊, 朱佳, 等.改良NHL-BFM-90方案治疗儿童青少年淋巴母细胞淋巴瘤患者远期疗效分析[J].中华血液学杂志, 2014, 35(12): 1083-9. doi: 10.3760/cma.j.issn.0253-2727.2014.12.008

    Sun X, Zhen Z, Zhu J, et al. Outcomes of modified NHL-BFM-90 protocol for children and adolescents with lymphoblastic lymphoma[J]. Zhonghua Xue Ye Xue Za Zhi, 2014, 35(12): 1083-9. doi: 10.3760/cma.j.issn.0253-2727.2014.12.008

    [11]

    Cortelazzo S, Ponzoni M, Ferreri AJ, et al. Lymphoblastic lymphoma[J]. Crit Rev Oncol, Hematol, 2011, 79(3): 330-43. doi: 10.1016/j.critrevonc.2010.12.003

    [12]

    Cortelazzo S, Ferreri A, Hoelzer D, et al. Lymphoblastic lymphoma[J]. Crit Rev Oncol Hematol, 2017, 113: 304-17. doi: 10.1016/j.critrevonc.2017.03.020

    [13]

    Rytting ME, Jabbour EJ, Jorgensen JL, et al. Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Munster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen[J]. Am J Hematol, 2016, 91(8): 819-23. doi: 10.1002/ajh.24419

    [14]

    Bersvendsen H, Kolstad A, Blystad AK, et al. Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma[J]. Acta Oncol, 2014, 53(5): 680-7. doi: 10.3109/0284186X.2013.855816

    [15]

    Azuma T, Tobinai K, Takeyama K, et al. Phase Ⅱ study of intensive post-remission chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia and lymphoblastic lymphoma: Japan Clinical Oncology Group Study, JCOG9402[J]. Jpn J Clin Oncol, 2012, 42(5): 394-404. doi: 10.1093/jjco/hys029

    [16]

    Tobinai K, Takeyama K, Arima F, et al. Phase Ⅱ study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004[J]. Cancer Sci, 2007, 98(9): 1350-7. doi: 10.1111/cas.2007.98.issue-9

    [17]

    Kang W, Hahn JS, Kim JS, et al. Nine-Year Survival of Lymphoblastic Lymphoma Patients[J]. Yonsei Med J, 2006, 47(4): 466-74. doi: 10.3349/ymj.2006.47.4.466

    [18] 杨萍, 赵伟, 景红梅. 30例T淋巴母细胞淋巴瘤患者临床特点及疗效分析[J].中国实验血液学杂志, 2016, 24(4): 1056-60. http://www.cnki.com.cn/Article/CJFDTotal-XYSY201604021.htm

    Yang P, Zhao W, Jing HM, et al. Analysis of Clinical Feature and Curative Efficacy of 30 Patients with T Cell Lymphoblastic Lymphoma[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2016, 24(4): 1056-60. http://www.cnki.com.cn/Article/CJFDTotal-XYSY201604021.htm

图(3)  /  表(3)
计量
  • 文章访问数:  2117
  • HTML全文浏览量:  378
  • PDF下载量:  573
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-06-25
  • 修回日期:  2017-10-19
  • 网络出版日期:  2024-01-12
  • 刊出日期:  2018-03-24

目录

/

返回文章
返回
x 关闭 永久关闭